The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients

Exclusion Criteria

• •Any of the following drugs or treatments were used within one year before screening: GLP-1RA, GLP-1 analogues, DPP-4 inhibitors or any other incretin analogues.
• •Long term (more than 7 consecutive days) intravenous administration, oral administration and intra-articular administration of corticosteroids received within 2 months prior to visit 1.
• •Used drugs with weight control effect or performed surgery that may lead to unstable weight within 2 months before screening, or is currently in the weight loss plan and not in the maintenance stage.
• •History of acute and chronic pancreatitis; History of myeloid C-cell carcinoma, MEN 2A or 2B syndrome, or related family history.
• •Clinically significant abnormal gastric emptying.
• •Any organ system tumors that have been treated or not treated within 5 years prior to visit 1.
• •Have received coronary angioplasty, coronary stent implantation, and coronary artery bypass surgery within 6 months prior to visit 1, and have experienced negligent compensatory heart failure (NYHA class III and IV of New York Heart Association), stroke or transient ischemic attack, unstable angina, myocardial infarction, and persistent and clinically significant arrhythmia.
• •Acute metabolic complications occurred within 6 months prior to visit 1.
• •Before screening, any laboratory test index meets the following standards: glutamic pyruvic transaminase\>2.5 times or glutamic oxaloacetic transaminase\>2.5 times; eGFR\<45ml\\/min\\/1.73m2； Fasting triglyceride\>5.64mmol /L.